Brokerages Set Cellectis S.A. (NASDAQ:CLLS) Target Price at $6.33

Shares of Cellectis S.A. (NASDAQ:CLLS) have been assigned a consensus recommendation of “Moderate Buy” from the five research firms that are currently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, three have issued a buy recommendation and one has given a strong buy recommendation to the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $6.3333.

A number of analysts have commented on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Cellectis in a research note on Wednesday, January 21st. Clear Str upgraded shares of Cellectis to a “strong-buy” rating in a research note on Tuesday, December 23rd. Finally, Jefferies Financial Group assumed coverage on shares of Cellectis in a report on Tuesday, February 17th. They issued a “buy” rating and a $7.00 target price on the stock.

Institutional Investors Weigh In On Cellectis

Large investors have recently added to or reduced their stakes in the business. Marshall Wace LLP lifted its holdings in Cellectis by 1,610.3% during the 4th quarter. Marshall Wace LLP now owns 178,473 shares of the biotechnology company’s stock valued at $864,000 after purchasing an additional 168,038 shares during the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new stake in shares of Cellectis during the 4th quarter worth about $15,385,000. Global Retirement Partners LLC bought a new stake in shares of Cellectis during the 4th quarter worth about $34,000. Millennium Management LLC grew its stake in Cellectis by 61.9% in the 3rd quarter. Millennium Management LLC now owns 57,740 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 22,080 shares during the last quarter. Finally, Citadel Advisors LLC acquired a new position in Cellectis in the 3rd quarter valued at about $633,000. Institutional investors own 63.90% of the company’s stock.

Cellectis Stock Up 0.6%

Shares of NASDAQ CLLS opened at $3.47 on Friday. The stock has a 50 day moving average price of $3.88 and a 200 day moving average price of $3.92. Cellectis has a 52 week low of $1.10 and a 52 week high of $5.48. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.49 and a quick ratio of 1.49.

About Cellectis

Cellectis is a clinical‐stage biopharmaceutical company specializing in the development of gene‐edited cell therapies for oncology. Founded in 1999 and headquartered in Paris, France, the company also maintains operations in New York City and Raleigh, North Carolina. Cellectis applies its proprietary TALEN genome editing platform to engineer allogeneic chimeric antigen receptor T‐cell (CAR‐T) candidates designed to target blood cancers and solid tumors.

The company’s core business activities encompass the discovery, development and manufacturing of off‐the‐shelf immunotherapies.